This IV Busulfex is an oncology product marketed and sold in the US and Canada, and through distributors in a number of other countries.
Otsuka will oversee the outsourced manufacturing of the product, while its US affiliate, Otsuka Pharmaceutical Development & Commercialization, will investigate clinical studies for potential new indications for IV Busulfex. Another Otsuka affiliate, Otsuka America Pharmaceutical, will market the product for its current indication in the US.